Search

EHA-SWG Diagnosis Teaser Meeting

On February 17 the 'teaser' meeting "Join the conversation on integrated diagnosis" with Prof MC Béne and key opinion experts took place virtually. Missed the live teaser? No worries, you can still watch the recording until March 17, 2022.

IVDR

As of May 26, 2022, the new EU In Vitro Diagnostic medical devices Regulation (IVDR) comes into effect.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Registration

Register here

The registration fee for the ESH-EBMT-EHA-IPIG 3rd Translational Research Conference: Bone Marrow Failure and Leukaemia Predisposition Syndromes is:
– 600€ for fully trained
– 300€ for in-training *
– 300€ Allied Health Professionals
– 600€ for Corporate
*A proof will be requested to confirm your status.…

Highlights from the SWG

Most impactful activitiesHIV Registry (NCT05231135)This unique retrospective and prospective EHA LyG European registry was initiated in August 2021, but recruitment was stalled due to objections from the local Ethics Committee.